- Stem cell therapy offers a promising treatment for drug-resistant epilepsy by targeting epileptogenesis and neuropsychiatric comorbidities rather than only suppressing seizures.
- Therapeutic mechanisms include direct engraftment, restoration of neurogenesis and immunomodulation via bystander effects; genetic engineering, extracellular vesicles and organoids enable personalised strategies.
- Despite promise, extensive preclinical and clinical research remains necessary to establish long-term safety and efficacy before widespread clinical adoption.
Stem Cells Transl Med. 2026 Aug 18;15(9):szag077. doi: 10.1093/stcltm/szag077.
ABSTRACT
Epilepsy represents as one of the most prevalent and serious neurological disorders, with approximately one-third of patients resistant to conventional treatments. Current pharmacologic therapies primarily suppress seizures without targeting the underlying epileptogenesis, resulting in unchanged long-term prognosis. At the same time, epilepsy surgery remains underutilized due to the requirement for extensive evaluations and specialized expertise. Stem cell-based therapy has emerged as a promising avenue, offering the potential to address both the neurological and neuropsychiatric aspects. This review summarizes recent preclinical and clinical studies on stem cell therapy in epilepsy, with a focus on their mechanisms of action, including direct engraftment, restoration of normal neurogenesis, and immunomodulation via bystander effect. Advances in genetic engineering, extracellular vesicle-based therapy, and patient-derived brain organoids offer more personalized treatment strategies. Although stem cell therapy holds significant promise as a treatment for epilepsy, further extensive research is required to establish its clinical safety and efficacy.
PMID:42697696 | DOI:10.1093/stcltm/szag077
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
⭐ My Revision List

